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Abstract 
Background: Pulmonary emphysema is characterized by alveolar destruction and 
persistent inflammation of the airways. Although IL-17A contributes to many chronic 
inflammatory diseases, it’s role in the inflammatory response of elastase-induced 
emphysema remains unclear  
Methods: In a model of elastase-induced pulmonary emphysema we examined the 
response of IL-17A-deficient mice, monitoring airway inflammation, static 
compliance, lung histology and levels of neutrophil-related chemokine and pro-
inflammatory cytokines in bronchoalveolar lavage (BAL) fluid. 
Results: Wild-type mice developed emphysematous changes in the lung tissue on day 
21 after elastase treatment, whereas emphysematous changes were decreased in IL-
17A-deficient mice compared to wild-type mice. Neutrophilia in BAL fluid, seen in 
elastase-treated wild-type mice, was reduced in elastase-treated IL-17A-deficient mice 
on day 4, associated with decreased levels of KC, MIP-2 and IL-1 beta. Elastase-
treated wild-type mice showed increased IL-17A levels as well as increased numbers 
of IL-17A+ CD4 T cells in the lung in the initial period following elastase treatment.  
Conclusions: These data identify the important contribution of IL-17A in the 
development of elastase-induced pulmonary inflammation and emphysema. Targeting 
IL-17A in emphysema may be a potential therapeutic strategy for delaying disease 
progression. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by 
progressive alveolar destruction and inflammation of the airways caused by noxious 
particles or gases. The precise mechanisms behind these pathological changes remain 
unclear, although oxidative stress, elastinolytic activity, and apoptosis of lung 
parenchymal cells are believed to contribute to the pathogenesis of the disease [1]. 
Current anti-inflammatory therapies are poorly effective in maintaining lung function 
and symptoms in COPD [2], therefore, new anti-inflammatory therapeutic strategies 
are needed. 
It has been reported that there are increased numbers of tertiary lymphoid 
follicles in the lungs of patients with COPD [3, 4], and that these follicles are 
organized structures with a B-cell core, T cells in the periphery, and dendritic cells 
capable of antigen presentation. [5-7]. Such observations have led to the hypothesis 
that COPD has an autoimmune component [8-10]. 
IL-17 is produced by inflammatory cells and targets structural cells such as 
epithelial cells, fibroblasts, and smooth muscle cells. The IL-17 family comprises six 
members (IL-17A to IL-17F). IL-17A and IL-17F display high sequence homology 
and can be secreted as homodimers, as well as IL-17A/F heterodimers, by both mouse 
and human cells [11]. These cytokines are produced by a subset of CD4+ 
lymphocytes known as T-helper (Th) 17 cells [12] and contribute to the development 
of autoimmune disease [13, 14]. IL-17A has been shown to induce the production of 
chemokines and inflammatory cytokines such as keratinocyte-derived chemokine 
(KC), macrophage inflammatory protein 2 (MIP-2), and IL-1β, that promote 
neutrophilic inflammation [15-17]. 
Recently, IL-17 has been shown to be associated with the development of lung 
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inflammatory diseases such as COPD [16, 18, 19]. Production of IL-17A was 
increased in the bronchial submucosa and subepithelium of COPD patients [18, 19]. 
Airway smooth muscle strips from COPD patients expressed IL-17RA and responded 
to IL-17 by inducing IL-8 production [16]. However, other studies failed to show any 
involvement of IL-17 in the development of COPD. Numbers of IL-17A+ cells in the 
airways of COPD patients were increased compared to healthy control subjects, but 
were not increased compared to smoking control subjects, and were not associated 
with increased neutrophilic inflammation [20]. Expression of IL-17 receptors in 
COPD was not different compared to non-COPD lung disease [21].  
Nonetheless, the role of IL-17A in the pathogenesis of COPD remains 
controversial and often has been based on indirect evidence. To address this question, 
we instilled porcine pancreatic elastase (PPE) in the trachea which first induces lung 
inflammation and subsequently results in alveolar wall destruction [22, 23]. These 
pathological changes closely mimic those seen in human emphysema. Here, we 
investigated the role of IL-17 in the development of elastase-inducible emphysema 
using IL-17A-deficient (IL-17A-/-) mice. 
 6
Methods 
Animals and treatment 
C57BL/6 wild-type (WT) mice were obtained from Charles River Japan. IL-
17A-/- mice were generated and backcrossed to C57BL/6 mice for 10 generations 
[24]. Ten week-old female WT and female IL-17A-/- mice were used in experiments.  
WT and IL-17A-/- mice received 3.5u of PPE (Sigma-Aldrich, St. Louis, MO, 
USA) in 30 µl of saline by intratracheal instillation on day 0 after being anesthetized 
with isoflurane. As control groups, WT and IL-17A-/- mice received 30 µl of saline 
on day 0. To evaluate emphysematous changes in the lungs, lung function was 
measured, and lung histology and morphometric measurements of air space size were 
assessed 21 days after PPE administration. On days 2, 4, and 21 after PPE 
administration, lungs were lavaged for analysis of cellular composition in 
bronchoalveolar lavage (BAL) fluid. 
To determine the timing of production of IL-17A in the airways, WT mice 
received PPE, and then lung tissue was taken at different time points (12hours, 1 day, 
2 day, 4 day, and 21 days) after PPE administration, and the levels of IL-17A in lung 
homogenates were measured. 
To assess the numbers of IL-17A and IFN-γ producing cells, WT mice 
received PPE or saline on day 0, and lung cells were isolated and IL-17A-producing 
cells were assessed by flow cytometry on day 2 after PPE administration. 
All experiments were performed in accordance with the National Institutes of 
Health guidelines. All protocols were approved by the Institutional Animal Care and 
Use Committees of Okayama University (Okayama, Japan). 
 
Determination of static lung compliance (Cst) 
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21 days after PPE administration, lung function was measured in 
tracheostomized mice using a computer-controlled small-animal ventilator (flexiVent; 
SCIREQ, Montreal, Canada) as described previously [25-27]. In brief, the mice were 
anesthetized with sodium pentobarbital (Kyoritsu Seiyaku, Tokyo, Japan) by 
intraperitoneal injection (12.5 mg/kg = 250 µl/mouse). The mice were 
tracheostomized with a 5 mm section of metallic tubing (= 18G cannula), ventilated at 
180 breaths/min with a tidal volume of 4 ml/kg and positive end-expiratory pressure 
of 3 cm H2O, and Cst was assessed. All data points were determined by flexiVent 
software (version 5.0).  
 
Lung histology and morphometric measurements of air space size 
On day 21 after PPE administration, mice were killed by intraperitoneal 
injection of pentobarbital sodium and lungs were inflated and fixed by intratracheal 
instillation of 10% formalin at a constant pressure of 25 cmH2O. The tissue was then 
embedded in paraffin and 2-µm thick sections were stained with hematoxylin and 
eosin (H&E). Air space enlargement was quantified by mean linear intercept (Lm) 
calculations in 20 randomly selected fields [28].  
 
BAL 
On days 2, 4, and 21 after PPE administration, lungs were lavaged via the 
tracheal tube with Hanks' balanced salt solution (2 x 1 ml, 37°C). The volume of the 
collected BAL fluid was measured in each sample, and the number of cells in the BAL 
fluid was counted. Cytospin slides were stained and differentiated in a blinded fashion 
by counting at least 200 cells under light microscopy [29].  
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Measurement of cytokines and chemokines 
KC, MIP-2 and IL-1β levels in the BAL fluid, and IL-17A levels in the 
supernatants of homogenized lungs were measured by ELISA as previously described 
[30]. For preparation of lung homogenates, lung tissue was frozen at -70°C 
immediately after euthanasia. Lung tissue was mixed with a PBS-0.1% Triton-X100 
solution containing proteinase inhibitors at a 1:2.5 ratio of weight per volume (BD 
Biosciences, San Diego, CA, USA). The specimens were homogenized and then 
centrifuged at 15,000 rpm for 15 min. The supernatants were frozen at -70°C until 
analysis [30]. All cytokine and chemokine ELISAs were performed according to the 
manufacturer’s directions (R&D Systems, Minneapolis, MN, USA). The limits of 
detection were 5 pg/ml for IL-17A, 2 pg/ml for KC, 1.5 pg/ml for MIP-2, and 3 pg/ml 
for IL-1β.    
 
Flow cytometry 
Lung cells were isolated as previously described following collagenase 
digestion [30]. Intracytoplasmic cytokine staining was performed as previously 
described [31, 32]. Briefly, after purification, cells were stimulated in vitro with 
phorbol myristate acetate (Sigma-Aldrich) and ionomycin (Sigma-Aldrich). Cells 
were stained for cell surface markers with PerCP-conjugated anti-CD4 (BD 
Biosciences). Then, cells were stained with PE-conjugated anti-IL-17A (BD 
Biosciences) or FITC-conjugated anti-IFN-γ (BD Biosciences), and analyzed on 
MACS Quant flow cytometer (Miltenyi Biotec, Auburn, CA, USA) with FlowJo 
software (TreeStar, Ashland, OR, USA). The numbers of cytokine-producing CD4 T 
cells per lung were calculated from the percentages of cytokine-producing cells and 
the numbers of CD4 T cells isolated from the lung. 
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Statistical analysis 
All results were expressed as the means ± standard error of the means (SEM). 
Statistical significance was detected by using 1-way ANOVA, followed by post-hoc 
analysis with the Tukey-Kramer test for comparisons between multiple groups. As 
measured values may not be normally distributed due to the small sample sizes, 
nonparametric analysis, Mann–Whitney U-test, was used for comparison of the 
numbers of cytokine-producing cells in figure 6B. Significance was assumed at p 
values of < 0.05. 
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Results  
Development of emphysema is reduced in IL-17A-/- mice 
To elucidate the role of IL-17A in the development of emphysema, we 
examined lung function 21 days following PPE treatment. Cst values were 
significantly higher in PPE-treated WT mice (mean±SEM: 0.106 ± 0.004 ml/cmH2O) 
compared with the values in saline-treated WT mice (0.065 ± 0.003 ml/cmH2O) and 
IL-17A-/- mice (0.067 ± 0.005 ml/cmH2O) 21 days after treatment (Fig. 1). PPE-
treated IL-17A-/- mice developed only small increases in Cst (0.084 ± 0.005 
ml/cmH2O) above saline-treated control mice (p <0.05), but the values were 
significantly lower than demonstrated in PPE-treated WT mice (p<0.01).  
Lung tissue was stained with H&E. No pathological differences were observed 
in WT and IL-17A-/- mice after saline treatment upon microscopic examination (Fig. 
2A and B). Intratracheal PPE instillation to WT mice produced air space enlargements 
and alveolar wall destruction (Fig. 2C) and these pathological changes were much less 
severe in IL-17A-/- mice. . As seen in Fig. 2D, the alveolar walls were less severely 
damaged in the lungs of IL-17A-/- mice treated with PPE compared to WT mice.  
To further characterize the development of emphysema in IL-17A-/- mice, we 
determined the airspace enlargement by measuring the mean linear intercept (Lm) in 
20 randomly selected fields from H&E stained tissue sections. After PPE treatment, 
Lm values in WT mice (118.6 ± 13.9 µm) were significantly increased compared to 
saline-treated WT mice (35.1 ± 0.9 µm) and IL-17-/- mice (36.5 ± 1.5 µm) (Fig. 2E). 
The increases in Lm values were significantly reduced in IL-17A-/- mice (87.5 ± 7.4 
µm) compared to WT mice 21 days after treatment with PPE (Fig. 2E). These 
histological and physiological evaluations demonstrated that IL-17A-/- animals were 
less susceptible to PPE-induced changes in the lung. 
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Elastase-induced pulmonary inflammation is reduced in IL-17A -/- mice 
Early onset lung inflammation is thought to be a major contributor to the 
development of emphysema [33]. The severity of the initial inflammation was 
compared in WT and IL-17A -/- mice 4 days after PPE treatment. In WT mice, 
inflammatory cell recruitment into the airways was increased after PPE treatment (Fig. 
3A). Increased total cell numbers were largely due to increased numbers of 
neutrophils and macrophages in BAL fluid (Fig. 3A). At this early stage, few 
histological changes were detected (data not shown). The increases in neutrophil 
numbers were significantly lower in IL-17A-/- mice compared to WT mice 4 days 
after PPE treatment (41.2 ± 5.4 vs 5.2 ±1.1 ×104/ml) (Fig. 3A). 
 We also assessed inflammatory cell population in BAL fluid 21 days after PPE 
treatment when emphysematous changes were already established. Numbers of 
lymphocytes in PPE-treated WT and IL-17A-/- mice were higher compared to saline-
treated WT and IL-17A-/- mice (Fig. 3B). However, no differences were observed 
between PPE-treated WT mice and PPE-treated IL-17A-/- mice in cellular 
composition at this point in time (Fig. 3B). 
 
Cytokine and chemokine levels in BAL fluid 
 To determine the basis for the altered inflammatory cellular recruitment in the 
IL-17A-/- mice, we assessed levels of BAL neutrophil-related chemokines (KC, MIP-
2) and pro-inflammatory cytokine (IL-1β) 4 days after PPE treatment. KC, MIP-2, 
and IL-1β levels were all higher in WT mice treated with PPE compared to mice 
which received saline (Fig. 4A). Levels of KC, MIP-2, and IL-1β in BAL fluid of IL-
17A-/- mice were significantly lower compared to WT mice following PPE treatment. 
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We next assessed IL-17A levels in lung homogenates because it could not be detected 
in BAL fluid. Levels of IL-17A in lung homogenate of PPE-treated WT mice tended 
to be higher compared to saline-treated WT mice, but were not significantly different 
(7.5 ± 0.5 and 5.4 ± 0.4 pg, respectively) (Fig 4B). 
 We also assessed chemokine and cytokine levels in BAL fluid on day 21 after 
PPE or saline treatment. At this point in time, KC, MIP-2, and IL-1β levels were all 
lower than limits of detection. Levels of IL-17A in lung homogenates of PPE-treated 
WT mice also were not higher compared to saline-treated WT mice (7.3 ± 1.0 and 5.3 
± 0.4 pg, respectively) (Fig 4C). 
 
Kinetics of IL-17A levels in the lung 
 To determine the timing of production of IL-17A in the airways following 
PPE treatment, we measured the levels of IL-17A in lung homogenates from WT 
mice at different time points. IL-17A levels were significantly higher early after PPE, 
on days 1 and 2 (10.5 ± 0.7 and 9.8 ± 0.7 pg, respectively) compared to baseline (day 
0) and 12 hours (4.8 ± 0.3 and 5.1 ± 0.4 pg, respectively) after PPE treatment (Fig. 5). 
The levels of IL-17A on days 4 or 21 (7.6 ± 0.4 and 7.6 ± 1.1 pg, respectively) 
following PPE treatment were not significantly higher than levels at baseline (day 0).  
 
Numbers of Th17 cells in the lung 
We next determined the numbers of IL-17 producing cells in the lungs of WT 
mice, 2 days following elastase treatment. Previous studies have shown that Th1 cells 
contribute to the pathogenesis of COPD, therefore, we also determined IFN-γ 
producing cells [34, 35]. Figure 6A shows the representative figures of percentages of 
IL-17A+ and IFN-γ+ CD4 T cells in the lung. IL-17A was detected in 4.78% of lung 
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CD4 T cells following PPE treatment (4.57% for IL-17A+ IFN-γ-, 0.21% for IL-17A+ 
IFN-γ+), whereas it was detected in 2.07% (1.72% for IL-17A+ IFN-γ-, 0.35% for IL-
17A+ IFN-γ+) following saline treatment. . Figure 6B summarizes the numbers of 
cytokine-producing cells in the lungs from WT mice. The numbers of IL-17A+ CD4 
T cells following PPE treatment were significantly higher compared to those 
following saline treatment (23.3 ± 4.0 vs 10.7 ± 2.2 ×104, p<0.05), whereas the 
numbers of IFN-γ + CD4 T cells were not different between saline-treated WT mice 
and PPE-treated WT mice (40.4 ± 9.1 and 31.8 ± 9.3 ×104, respectively). We assessed 
the cellular composition in BAL fluid of WT mice and IL-17A-/- mice on day 2 after 
PPE treatment. At this early stage, the numbers of neutrophils were significantly 
lower in IL-17A-/- mice compared to WT mice (attached file). These data suggest that 
elastase increases numbers of Th17 cells and secretion of IL-17A in the lungs, and 
this contributes to acute neutrophilic airway inflammation, and subsequently results in 
emphysematous changes in the airways.  
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Discussion 
It has been reported that Th17 cells are a critical component of the adaptive 
immune response and IL-17 has been implicated in chronic inflammatory and 
autoimmune diseases [13, 14]. There has been much interest in the role of the 
adaptive immune response in COPD since COPD in humans is associated with the 
development of lymphoid follicles in the lung [3, 4]. Moreover, patients with COPD 
have evidence of anti-elastin antibodies and Th1 responses, suggesting an 
autoimmune component [8, 9]. Recently, numbers of IL-17A+ cells in the airways 
[18-20, 36] and peripheral blood [37] of COPD patients have been reported to be 
increased. These studies suggested an association between Th17 and COPD, however, 
the role for IL-17A in disease development is not defined.   
In the present study, to elucidate the role of IL-17A in the development of 
emphysema, we investigated PPE-induced initial inflammation and subsequent late 
phase emphysematous change in IL-17A-/- and WT mice. We demonstrated that both 
the PPE-induced acute phase inflammation and the late phase emphysematous 
changes seen in WT mice were attenuated in IL-17A-/- mice. Increased levels of 
neutrophil-related chemokines such as KC, MIP-2 and IL-1β seen in the BAL fluid of 
WT mice were also significantly reduced in IL-17A-/- mice following PPE 
administration. These data, for the first time, indicated that IL-17A may play a role in 
the elastase-induced pulmonary pathology.  
We observed that levels of IL-17A in the lungs were increased in the acute 
phase following PPE treatment. The numbers of IL-17A producing cells in the lung 
were also increased following PPE treatment. Thus, elastase administration leads to 
increases in both IL-17-producing cells and levels of IL-17A. These results were 
consistent with the observations showing that IL-17A expressing cells were increased 
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in the airways of COPD patients. For example, numbers of IL-17A+ cells in the 
bronchial submucosa were increased in COPD compared to smokers without COPD 
and nonsmoking control subjects [19]. The sputum concentrations of IL-17A in 
COPD were increased compared to patients with asthma [19]. It has also been 
reported that cigarette smoke extract had an adjuvant effect on CD4 T cell activation 
and differentiation to Th17 cells in vitro [38]. These data suggest that smoking 
induces both IL-17A secretion in the airways and increases differentiation of Th17 
cells. 
IL-17A has been shown to accumulate [39] and activate neutrophils [40], and 
enhance epithelial production of IL-8 [41]. It has also been reported that IL-17A acts 
directly on epithelial cells, airway fibroblasts and smooth muscle cells to induce the 
secretion of neutrophil-recruiting chemokines [42]. Airway smooth muscle strips from 
COPD patients expressed IL-17RA and responded to IL-17A by inducing IL-8 
production [16]. Rodents lack a direct homologue of IL-8, but the chemokines KC and 
MIP-2 are regarded as functional homologues and have been found to contribute to 
the pathology of a number of neutrophil-dependent animal models of disease [43]. In 
the present study, levels of KC and MIP-2 were increased in WT mice following PPE 
treatment, and these levels were lower in IL-17A-/- mice. Thus IL-17A may induce 
neutrophil chemotactic factor production, KC and MIP-2, and contribute to 
neutrophilic airway inflammation following PPE treatment.  
Th17 cells have been shown to produce more inflammatory cytokines, such as 
IL-1β, compared with regulatory T cells and other T-helper cells [44]. In the present 
study, the levels of IL-1β in WT mice were increased 4 days after intratracheal PPE 
instillation and levels were significantly lower in IL-17A-/- mice. Although the  link 
between acute inflammatory changes and the subsequent development of 
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emphysematous changes requires further investigation, it is likely that in addition to 
KC and MIP-2, increased levels of proinflammatory cytokines such as IL-1β prolong 
and enhance acute inflammation and contribute to later emphysema. In this way, IL-
17A-mediated pathways might play a central role in the pathophysiological events. 
Chen et al. recently reported that IL-17RA-deficient mice failed to develop 
emphysema after 6 months of cigarette smoke exposure in contrast to wild-type mice 
[38]. In their study, the wild-type mice which received 6 months smoking exposure 
showed higher levels of IL-17 in BAL fluid compared to sham-exposed mice. IL-
17RA-/- mice showed lower levels of monocyte chemotactic protein-1 (MCP-1) in 
BAL fluid and lower expression of the matrix metalloproteinase (MMP)-9 and MMP-
12 in the lung, compared to wild-type mice, suggesting an important role for IL-17RA 
in macrophage recruitment to the inflamed lung and for development of emphysema. 
They saw no differences in KC levels in BAL fluid between IL-17RA-/- mice and 
wild-type mice when emphysema was established, similar to our study. In the present 
study, however, we have shown that neutrophil-related chemokines such as KC and 
MIP-2 were increased at a relatively early stage following elastase treatment, which 
was associated with increased levels of IL-17A, and increased numbers of neutrophils 
in the airways, suggesting an important role for IL-17A in the recruitment of 
neutrophils at a relatively early stage. IL-17RA has at least three ligands including IL-
17A, IL-17F, and IL-25. In the present study, we demonstrated the importance of IL-
17A for emphysema using IL-17A-/- mice. Shan et al have also shown that cigarette 
smoke-induced emphysema is mediated by IL-17A in mice [45]. Regarding other 
ligands for IL17RA, IL-25 has been reported to be associated with both Th2 and Th17 
immune responses [46], however, little is known about the role of this cytokine in 
emphysema development. Expression of both IL-17A and IL-17F were increased in 
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the airways of COPD subjects in both inflammatory cells as well as in the airway 
epithelium [18, 19]. In contrast, numbers of IL-17F+ cells were not increased in 
COPD compared to control subjects [20].  
In the present study, elastase-induced emphysematous changes of the lung in 
IL-17A-/- mice were reduced, but not completely attenuated compared to WT mice, 
suggesting that IL-17A may be essential but not sufficient for the full development of 
elastase-induced emphysema. Previous studies have shown that Th1 cells contribute 
largely to the inflammatory cascade of events related to the pathogenesis of COPD 
[34, 35]. It has also been reported that Th2 cells may be important in the inflammatory 
response of the disease [47-49]. Using IL-18 transgenic mice with disruption of the 
IL-13 gene, Hoshino et al. have shown that IL-18 and IL-13 might have important 
roles in the pathogenesis of emphysema [50]. Recently, it has also been reported that 
overexpression of IL-18 induced emphysema via IFN-γ and IL-17A, and induced 
mucus metaplasia via IL-13 [51]. Chronic cigarette smoke has been shown to induce 
both Th1 and Th17 cells in mice [52]. Thus, although Th17 cells may play an 
important role in the pathogenesis of emphysema, their role is not exclusive and Th1 
and Th2 cells may also have contributory roles. Further understanding of how these 
helper T cell subsets interact and orchestrate a pathological response to smoking will 
be essential if we are to successfully intervene in the development and progression of 
COPD and emphysema. 
 
Conclusions 
We demonstrated that IL-17A plays an important role to the development of 
PPE-induced acute phase neutrophilic inflammation and subsequent emphysematous 
change of the lung, which was associated with increased levels of neutrophil-related 
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chemokines such as KC, MIP-2 and IL-1β. Numbers of Th17 cells as well as IL-17A 
levels in the lung were increased following treatment with elastase. Our data suggest 
that targeting IL-17A in emphysema may be a hopeful therapeutic strategy for 
improving clinical outcomes and for delaying disease progression.  
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Figure Legends 
Figure 1. Static lung compliance (Cst) values on day 21 after intratrachial instillation 
of porcine pancreas elastase (PPE) or saline. The results are expressed as means ± 
SEM (n=12 in each group). *p<0.01 compared to WT saline and IL-17A-/- saline. 
**p<0.05 compared to WT saline and IL-17A-/- saline. #p<0.01 versus WT PPE. 
 
Figure 2. Morphometric assessment performed on day 21 after instillation of PPE or 
saline. Representative photographs of lungs of WT mice treated with saline (A), IL-
17A-/- mice treated with saline (B), WT mice treated with PPE (C), and IL-17A-/- 
mice treated with PPE (D) groups. (E) Mean linear intercepts (Lm) values of alveoli. 
Lm values were obtained as described in Methods. Bar = 200µm. Data represent the 
mean ± SEM (n=12 in each group). *p<0.01 compared to WT saline and IL-17A-/- 
saline. #p<0.05 versus WT PPE.  
 
Figure 3. Cellular composition in bronchoalveolar lavage (BAL) fluid after 
intratracheal instillation of PPE or saline. BAL fluid was obtained as described in 
Methods. Data represent the mean ± SEM (n=12 in each group). (A) Cellular 
composition in BAL fluid on day 4 after intratracheal instillation of PPE or saline. 
*p<0.01 compared to WT saline and IL-17A-/- saline. #p<0.05 versus WT PPE. 
##p<0.01 versus WT PPE. (B) Cellular composition in BAL fluid on day 21 after 
intratracheal instillation of PPE or saline. *p<0.05 compared to WT saline and IL-
17A-/- saline.  
 
Figure 4. Cytokine and chemokine levels in the BAL fluid and lung homogenates. 
(A) KC, MIP-2, and IL-1β levels in BAL fluid. BAL fluid was obtained from the 
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same groups as described in Fig. 3A. Data represent the mean ± SEM (n=12 in each 
group). *p<0.01 compared to WT saline and IL-17A-/- saline. #p<0.05 versus WT 
PPE. ##p<0.01 versus WT PPE. (B) IL-17A levels in lung homogenates on day 4 
after intratracheal instillation of PPE or saline. Data represent the mean ± SEM (n=8 
in each group). (C) IL-17A levels in lung homogenates on day 21 after intratracheal 
instillation of PPE or saline. Data represent the mean ± SEM (n=8 in each group). 
 
Figure 5. IL-17A levels in the lung. IL-17A levels in lung homogenates of WT mice 
after intratracheal instillation of PPE were measured by ELISA as described in 
Methods. The results for each group are expressed as means ± SEM (n=8 in each 
group). *p <0.01, day 0 and day 0.5 versus day 1 and day 2. 
 
Figure 6. Intracellular detection of IL-17A and IFN-γ in lung CD4+ T cells from WT 
mice 2 days after elastase administration. (A) Percentages of IL-17A+ and IFN-γ+ T 
cells following saline treatment (Saline group) or PPE treatment (PPE group).  
Intracellular IL-17A and IFN-γ were assessed as described in Methods. The data 
shown are representative of two independent experiments. (B) The numbers of IL-
17A+ and IFN-γ+ CD4 T cells in the lung of WT mice. The numbers of IL-17A+ CD4 
T cells and IFN-γ+ CD4 T cells were calculated as described in Methods. Groups are 
the same as in (A). Data represent the mean ± SEM (n=6 in each group). *p<0.05 
versus saline-treated group. 
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